YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Entelos Makes Post IPO Report


By John Russell

Oct. 16, 2006 | Here comes the public scrutiny. After netting $16.6 million in a public offering on London's Alternative Investment Market last April, Entelos released interim six-month results in the middle of September. The biosimulation specialist reported revenues of $15.2 million and income of roughly $5.3 million.

In the chairman and CEO review section of the report, Entelos said a substantial portion of the revenue, "most of which was reflected as deferred revenue on the Company's previous year-end, resulted from progress achieved on a large multi-year contract." The company reported $4 million of the IPO was used to pay down debt, and indicated current cash and short-term investments totaled $15.8 million at the end of June.

Collaborations singled out for notice included a five-year extension of its deal with Johnson & Johnson; a two-year collaboration with Roche in metabolic diseases; establishment of an in silico Type 1 Diabetes center with the American Diabetes Association; progress with Unilever, Pfizer, and Lilly; and a "post-period" deal with Novartis in multiple disease areas.

Email John Russell.

Subscribe to Bio-IT World  magazine.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact  Jay Mulhern, (781) 972-1359, jmulhern@healthtech.com.